Montelucaste Tecnigen (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, E4 and related molecules from binding. This inhibition reduces bronchoconstriction, mucus production, and inflammation in the airways and nasal passages, improving breathing and reducing allergic symptoms.

The appropriate dose of Montelucaste Tecnigen is determined by the prescribing healthcare professional based on the patient’s age, weight, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for montelukast in pregnancy and lactation are limited. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing women. Patients should discuss their individual situation with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who prefer a once‑daily tablet, though it may be used in combination with other controller medications for optimal control.

Montelucaste Tecnigen tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

The medication is taken orally, usually once daily in the evening, with or without food. Swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by the healthcare professional.

Serious but rare risks include severe allergic reactions such as angioedema or anaphylaxis, neuropsychiatric events like depression or suicidal thoughts, and rare skin conditions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelucaste Tecnigen is contraindicated in patients with known hypersensitivity to montelukast or any of the tablet’s excipients. It should be used with caution in individuals with severe liver impairment or those taking interacting medications, and it is not recommended for patients with uncontrolled severe asthma without a rescue inhaler.